Motif Neurotech completes first-in-human implant of miniature brain pacemaker

To-scale rendering of the prototype Motif DOT microstimulator used in first-in-human and large animal studies. [Image courtesy of Motif Neurotech]Motif Neurotech today announced new research highlighting the use of its millimeter-sized brain stimulator in a human subject.

Houston-based Motif Neurotech develops a miniature brain pacemaker designed to precisely stimulate the brain. It restores healthy circuit activity to treat mental health disorders. The pea-sized implant, which goes in during a 20-minute outpatient procedure, has capabilities for at-home therapy.

Motif Neurotech says it should produce minimal side effects compared to drugs. Its lead product treats treatment-resistant depression (TRD), a form of major depressive disorder (MDD).

The company conducted the study in collaboration with researchers at Rice University, Baylor College of Medicine and UTHealth Houston. The human procedure took place at Baylor St. Luke’s Medical Center.

I…

Read more
  • September 18, 2023
  • 0

Medtronic neuromod vet joins miniature brain pacemaker developer Motif Neurotech as CTO

Steven Goetz. [Image courtesy of Motif Neurotech]Minimally invasive bioelectronic maker Motif Neurotech announced today that it named Steven Goetz as its chief technology officer (CTO).

Goetz joins after spending more than 26 years in the Neuromodulation unit at Medtronic. There, he led engineering and innovation initiatives for implantable device therapies for a wide range of diseases.

Houston-based Motif Neurotech develops a miniature brain pacemaker designed to stimulate the brain. The company aims for the device to restore healthy circuit activity and treat mental health disorders.

Inserted during a 20-minute procedure, the pea-sized device goes in the skull, above — and not touching — the brain. It can deliver at-home therapy with minimal side effects compared to drugs or less precise brain stimulation. Motif Neurotech has its lead product under development for treatment-resistant depression.

Goetz’s responsibilities include leading all R&…

Read more
  • July 24, 2023
  • 0